Pfizer and Novo Nordisk seem to want Metsera bad. Analysts are wondering, though: is the obesity biotech really worth this much effort?

Vancouver, Canada, November 4th, 2025, FinanceWire Equity Insider News Commentary – The precision medicine sector reached ...

A biotech stock with strong FDA approval odds this November may see limited upside amid a full valuation and a pending lawsuit.

2. Mergers and acquisitions are picking up: So far this year, buyouts have boosted several biotech stocks. Some standouts: Regulus Therapeutics went up 120%; 89bio went up 85%; Chimerix gained 69% and ...

Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company"), a leader in the development of differentiated targeted radiotherapies, announced today that Sandesh Seth, Chairman and CEO will be ...

Q VYJUVEK revenue and $623.2 million since U.S. launch VYJUVEK launched in Germany in 3Q; launched in France and Japan in ...

Advisers, some employees and some board members are scoring payouts ranging from $75,000 to $53 million.

The upcoming EU Biotech Act may be more prominently focused on health. But it will also significantly impact food and food ...

A well-crafted narrative helps investors see not just the molecule in front of them, but the broader therapeutic and ...

In the past week or so, a gold and silver miner, a struggling offshore driller, and a biotech saw some huge insider buying.

COULD ACTUALLY BE MUCH MORE ACCURATE. A MARY SALADNA IS IN THE NEWSROOM AND MARY THE RESULTS AREN’T GOOD. NO, THEY’RE NOT, BUT THE RESULTS ARE MORE REALISTIC AND MORE PROOF THAT BODY COMPOSITION ...

The prevalence of obesity in the United States could rise sharply under a definition of obesity released earlier this year by the Lancet Diabetes and Endocrinology Commission. Additionally, the ...